Literature DB >> 10210152

Nitric oxide, superoxide radicals and mast cells in pathogenesis of indomethacin-induced small intestinal lesions in rats.

A Konaka1, M Nishijima, A Tanaka, T Kunikata, S Kato, K Takeuchi.   

Abstract

We investigated the pathogenic mechanism of indomethacin-induced small intestinal lesions, in relation to nitric oxide (NO), superoxide radicals and mast cells. Rats received indomethacin (1-6 mg/kg) s.c. once daily for 3 days, and the small intestine was examined for lesions 24 hr after the final administration of indomethacin. Indomethacin caused hemorrhagic lesions in the small intestine, mostly in the jejunum and ileum, in dose- and time-dependent manners, with concomitant increase of mucosal microvascular permeability. This treatment also caused an increase of inducible NO synthase (iNOS) activity with the expression of its mRNA, myeloperoxidase (MPO) activity as well as thiobarbituric acid reactants (TRBAS) in the mucosa, and the changes in iNOS activity preceded those in MPO activity and TRBAS as well as lesion development. These lesions induced by indomethacin were prevented by aminoguanidine (a selective inhibitor of iNOS), dexamethasone (an inhibitor of iNOS mRNA transcription), allopurinol (a xanthine oxidase inhibitor), hydroxyurea (a neutrophil reducing agent) and FR167653 (an inhibitor of interleukin-1/tumor necrosis factor-alpha production) as well as 16,16-dimethyl prostaglandin E2ń. Likewise, the severity of these lesions was also reduced by mast cell stabilizers FPL-52694 and disodium cromoglycate and a lipoxygenase inhibitor TMK-688, but not affected by tripelennamine (a histamine H1-receptor antagonist) or methysergide (a serotonin receptor antagonist). These results suggest that: 1) the pathogenic mechanism of indomethacin-induced small intestinal lesions involves superoxide radicals as well as NO produced by iNOS, 2) the deleterious effect of NO may be accounted for by the cytotoxic action of peroxynitrite, produced from NO in the presence of superoxide radicals, and 3) the mast cells may also be involved in the process of small intestinal ulceration, although the mediator responsible remains undefined.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10210152

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  18 in total

1.  Epidermal growth factor prevents gut atrophy and maintains intestinal integrity in rats with acute pancreatitis.

Authors:  Dong-Li Chen; Wei-Zhong Wang; Jun-Yi Wang
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

2.  New dogmas or old?

Authors:  B J R Whittle
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

3.  Factors involved in upregulation of inducible nitric oxide synthase in rat small intestine following administration of nonsteroidal anti-inflammatory drugs.

Authors:  Koji Takeuchi; Aya Yokota; Akiko Tanaka; Yuka Takahira
Journal:  Dig Dis Sci       Date:  2006-07       Impact factor: 3.199

Review 4.  Present status and strategy of NSAIDs-induced small bowel injury.

Authors:  Kazuhide Higuchi; Eiji Umegaki; Toshio Watanabe; Yukiko Yoda; Eijiro Morita; Mitsuyuki Murano; Satoshi Tokioka; Tetsuo Arakawa
Journal:  J Gastroenterol       Date:  2009-07-01       Impact factor: 7.527

5.  Nitric oxide inhibitors ameliorate indomethacin-induced enteropathy in rats.

Authors:  G Parasher; L Frenklakh; T Siddiqui; J Nandi; R A Levine
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

6.  16,16-Dimethyl prostaglandin E2 inhibits indomethacin-induced small intestinal lesions through EP3 and EP4 receptors.

Authors:  Tomonori Kunikata; Akiko Tanaka; Tohru Miyazawa; Shinichi Kato; Koji Takeuchi
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

7.  Mast cells are involved in the pathogenesis of indomethacin-induced rat enteritis.

Authors:  Tetsuya Okayama; Norimasa Yoshida; Kazuhiko Uchiyama; Tomohisa Takagi; Hiroshi Ichikawa; Toshikazu Yoshikawa
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

8.  In vitro and in vivo protection against indomethacin-induced small intestinal injury by proton pump inhibitors, acid pump antagonists, or indomethacin-phosphatidylcholine.

Authors:  Yun Jeong Lim; Tri M Phan; Elizabeth J Dial; David Y Graham; Lenard M Lichtenberger
Journal:  Digestion       Date:  2012-08-14       Impact factor: 3.216

9.  Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents.

Authors:  Tiziano Croci; Marco Landi; Anne-Marie Galzin; Pietro Marini
Journal:  Br J Pharmacol       Date:  2003-07-29       Impact factor: 8.739

10.  Prevention of NSAID-Induced Small Intestinal Mucosal Injury: Prophylactic Potential of Lansoprazole.

Authors:  Kazuhide Higuchi; Yukiko Yoda; Kikuko Amagase; Shinichi Kato; Satoshi Tokioka; Mitsuyuki Murano; Koji Takeuchi; Eiji Umegaki
Journal:  J Clin Biochem Nutr       Date:  2009-08-28       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.